MedTrace Logo

Safety and Tolerability of Trospium Chloride and Metformin Hydrochloride in Healthy Subjects

NCT00986401 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2011-12-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate the safety and tolerability of trospium chloride (Sanctura XR™) and metformin hydrochloride (Glucophage) when co-administered.

Conditions

  • Healthy

Interventions

DRUG

Trospium Chloride (Sanctura XR®)

extended release, 60 mg, oral daily

DRUG

Metformin hydrochloride (Glucophage®)

immediate release, 500mg

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2009-11-30
Completion
2009-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00986401 on ClinicalTrials.gov